John Manusu
Director Ejecutivo en PrIME Biologics Pte Ltd. .
Perfil
John Manusu is currently the Managing Director and Director at PrIME Biologics Pte Ltd.
He previously worked as the Non-Executive Chairman at Memphasys Ltd.
from 2012 to 2013 and as a Director and Director-Investor Relations at Arturus Capital Ltd.
from 1987 to 2007.
Cargos activos de John Manusu
| Empresas | Cargo | Inicio |
|---|---|---|
PrIME Biologics Pte Ltd.
 PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Director Ejecutivo | 01/01/1985 |
Antiguos cargos conocidos de John Manusu.
| Empresas | Cargo | Fin |
|---|---|---|
| MEMPHASYS | Presidente | 29/11/2013 |
Arturus Capital Ltd.
 Arturus Capital Ltd. Financial ConglomeratesFinance Arturus Capital Ltd. is an investment company that holds interests in mining and gas projects. The company was founded on May 31, 1972 and is headquartered in North Perth, Australia. | Director/Miembro de la Junta | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| MEMPHASYS | Health Technology |
| Empresas privadas | 2 |
|---|---|
Arturus Capital Ltd.
Arturus Capital Ltd. Financial ConglomeratesFinance Arturus Capital Ltd. is an investment company that holds interests in mining and gas projects. The company was founded on May 31, 1972 and is headquartered in North Perth, Australia. | Finance |
PrIME Biologics Pte Ltd.
PrIME Biologics Pte Ltd. BiotechnologyHealth Technology PrIME Biologics Pte Ltd. develops disposable therapeutic plasma manufacturing process. Its process doubles product yields while increasing product safety and removing viruses, bacteria, endotoxins, and prions. The firm’s process reduces the time it takes to produce multiple plasma products from days to hours. The company is headquartered in Singapore. | Health Technology |
- Bolsa de valores
- Insiders
- John Manusu
